NFKB1 and ulcerative colitis: In line with the present work, GSK-3β was reported to be activated in ulcerative colitis, where it positively regulated NF-κB (Uddin et al., 2013), which then controls pro-inflammatory mediators like TNF-α (Demarchi et al., 2003).